COYA

Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces that the Company will present an overview of the ongoing ALSTARS trial, outlining its design and approach to targeting neuroinflammation, at the 5th ALS Drug Development Summit which will take place June 2–4, 2026, in Boston, MA. The details for the poster presentation, which will be presented by Tyrell Simkins, D.O., Ph.D., Senior Director, Clinical Development, are below: Poster Title: ALSTARS: A Precision Immunomodulatory Phase 2 Trial of COYA 302 Targeting Regula

DEFA14A - Coya Therapeutics, Inc. (0001835022) (Filer)

DEF 14A - Coya Therapeutics, Inc. (0001835022) (Filer)

8-K - Coya Therapeutics, Inc. (0001835022) (Filer)

424B5 - Coya Therapeutics, Inc. (0001835022) (Filer)

10-Q - Coya Therapeutics, Inc. (0001835022) (Filer)

8-K - Coya Therapeutics, Inc. (0001835022) (Filer)

Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces its financial results for the quarter ended March 31, 2026 and provides a corporate update. "We are off to a strong start in 2026, building on the clinical and scientific progress achieved last year," said Arun Swaminathan, Ph.D., Chief Executive Officer of Coya. "The ALSTARS trial is now in full recruitment mode, and we maintain our guidance for a 1Q 2027 topline readout. With a solid foundation and balance sheet in place we are well positioned to deliver on our prior

Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for COYA 302, a proprietary investigational biologic combination therapy with a dual mechanism of action, for the treatment of amyotrophic lateral sclerosis (ALS). The FDA Fast Track Designation is a program designed to facilitate and expedite the development and review of drugs and biologics intended to treat serious or life-threatening conditions. Its primary purp

4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

3 - Coya Therapeutics, Inc. (0001835022) (Issuer)

The study evaluated serum biomarkers of lipid peroxidation, systemic inflammation, and axonal integrity in 100 randomly selected patients with ALS and included 100 healthy controls to allow for a meaningful comparison Levels of 4-hydroxy-2-nonenal (4-HNE), lipopolysaccharide binding protein (LBP), and neurofilament light chain (NfL) at diagnosis were significantly correlated with length of survival in patients with ALS In a previously reported Investigator Initiated Trial that studied the combination of subcutaneous low-dose interleukin 2 (LD IL-2) and CTLA-4 Ig, these biomarkers of survival were reduced from baseline Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a

8-K - Coya Therapeutics, Inc. (0001835022) (Filer)

Additions Bring Extensive Capital Markets and Business Transaction Expertise to Company as it Advances Pegtarazimod into Late-Stage Clinical Trials ReAlta Life Sciences Inc., a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to revolutionize the treatment of inflammatory disorders, today announced the appointments of Howard Berman, Ph.D., as Chairman and Chief Executive Officer and Kia Motesharei, Ph.D., as President and Chief Operating Officer. Dr. Berman, who has served as Executive Chairman since November 2025, will lead ReAlta's overall strategy, clinical development, and corporate execution, while Dr.

EFFECT - Coya Therapeutics, Inc. (0001835022) (Filer)

424B3 - Coya Therapeutics, Inc. (0001835022) (Filer)

Study results demonstrate significant reduction in regulatory T cell (Treg) function and significant increase in circulating pro-inflammatory cytokines and chemokines in patients with FTD Low-dose IL-2 plus CTLA-4 Ig has previously demonstrated restoration of regulatory T-cell function together with reduction of inflammatory cytokines and monocyte activation in treated patients Findings of this biomarker study are consistent with previously reported results of an Investigator-Initiated-Trial of LD IL-2 and CTLA-4 Ig in patients with FTD Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance Treg

S-3 - Coya Therapeutics, Inc. (0001835022) (Filer)

10-K - Coya Therapeutics, Inc. (0001835022) (Filer)

8-K - Coya Therapeutics, Inc. (0001835022) (Filer)

Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, provides a corporate update and announces its financial results for the year ended December 31, 2025. Corporate Highlights FY 2025 to Date COYA 302 Successfully launched the ALSTARS Phase 2 trial evaluating COYA 302 for the treatment of ALS and now actively enrolling and dosing patients across ~25 clinical sites in the U.S. and Canada. Clinical Trial Application (CTA) acceptance from Health Canada to proceed with the COYA 302 ALSTARS Phase 2 trial in Canada. Announced

─ Virtual Webinar on Tuesday, Feb. 17 at 3 p.m. ET / 12 p.m. PT ─ Will feature discussion and insights from Fred Grossman, D.O., FAPA; Stanley Appel, M.D.; and James Berry, M.D., MPH — accomplished physicians specializing in neurological disorders Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorder, today announced it will host a live webinar on February 17, 2026 at 3:00 p.m. ET/ 12:00 p.m. PT exploring the evolving ALS treatment landscape. Titled ‘Inside the Evolving ALS Landscape: Biology, Innovation, and Clinical Progress',

SCHEDULE 13G/A - Coya Therapeutics, Inc. (0001835022) (Subject)

8-K - Coya Therapeutics, Inc. (0001835022) (Filer)

- Dr. Reddy's Laboratories, Inc., a subsidiary of Coya's current strategic collaborator, makes a $10 million investment - Greenlight Capital, Coya's largest institutional shareholder, is the only other investor participating in the offering Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announced today that it has entered into a definitive securities purchase agreement for the purchase and sale of an aggregate of 2,522,727 shares of its common stock in a private placement at a price of $4.40 per share. The off